{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:18:28Z","timestamp":1791497908153,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2020-02200"],"award-info":[{"award-number":["2020-02200"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2017-01920"],"award-info":[{"award-number":["2017-01920"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["K2015-99X-22877-01-6"],"award-info":[{"award-number":["K2015-99X-22877-01-6"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["Wallenberg Clinical Scholar 2015.0320"],"award-info":[{"award-number":["Wallenberg Clinical Scholar 2015.0320"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sk\u00e5ne Center of Excellence in Health"},{"DOI":"10.13039\/501100003849","name":"IngaBritt och Arne Lundbergs Forskningsstiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003849","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004200","name":"Olle Engkvists Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006741","name":"Stiftelsen Frimurare Barnhuset i Stockholm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006741","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hemolysis is a cardinal feature of hemolytic uremic syndrome (HUS) and during hemolysis excess arginase 1 is released from red blood cells. Increased arginase activity leads to reduced L-arginine, as it is converted to urea and L-ornithine, and thereby reduced nitric oxide bioavailability, with secondary vascular injury. The objective of this study was to investigate arginase release in HUS patients and laboratory models and correlate arginase levels to hemolysis and kidney injury.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Two separate cohorts of patients (n\u2009=\u200947 in total) with HUS associated with Shiga toxin-producing enterohemorrhagic <jats:italic>E. coli<\/jats:italic> (EHEC) and pediatric controls (n\u2009=\u200935) were investigated. Two mouse models were used, in which mice were either challenged intragastrically with <jats:italic>E. coli<\/jats:italic> O157:H7 or injected intraperitoneally with Shiga toxin 2. An in vitro model of thrombotic microangiopathy was developed in which Shiga toxin 2- and <jats:italic>E. coli<\/jats:italic> O157 lipopolysaccharide-stimulated human blood cells combined with ADAMTS13-deficient plasma were perfused over glomerular endothelial cells. Two group statistical comparisons were performed using the Mann\u2013Whitney test, multiple groups were compared using the Kruskal\u2013Wallis test followed by Dunn\u2019s procedure,\u00a0the Wilcoxon signed rank test was used\u00a0for paired data, or linear regression for continuous variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>HUS patients had excessively high plasma arginase 1 levels and activity (conversion of L-arginine to urea and L-ornithine) during the acute phase, compared to remission and controls. Arginase 1 levels correlated with lactate dehydrogenase activity, indicating hemolysis, as well as the need for dialysis treatment. Patients also exhibited high levels of plasma alpha-1-microglobulin, a heme scavenger. Both mouse models exhibited significantly elevated plasma arginase 1 levels and activity. Plasma arginase 1 levels correlated with lactate dehydrogenase activity, alpha-1-microglobulin and urea levels, the latter indicative of kidney dysfunction. In the in vitro model of thrombotic microangiopathy, bioactive arginase 1 was released and levels correlated to the degree of hemolysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Elevated red blood cell-derived arginase was demonstrated in HUS patients and in relevant in vivo and in vitro models. The excessively high arginase levels correlated to the degree of hemolysis and kidney dysfunction. Thus, arginase inhibition should be investigated in HUS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-04824-x","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T12:02:53Z","timestamp":1704369773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Red blood cell-derived arginase release in hemolytic uremic syndrome"],"prefix":"10.1186","volume":"22","author":[{"given":"Niklas","family":"Friberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Arvidsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashmita","family":"Tontanahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Charlotte","family":"Kristoffersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Gram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard S.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-7658","authenticated-orcid":false,"given":"Diana","family":"Karpman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"issue":"2","key":"4824_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/joim.12546","volume":"281","author":"D Karpman","year":"2017","unstructured":"Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med. 2017;281(2):123\u201348.","journal-title":"J Intern Med"},{"issue":"7","key":"4824_CR2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654\u201366.","journal-title":"N Engl J Med"},{"key":"4824_CR3","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","volume":"3","author":"JA Kremer Hovinga","year":"2017","unstructured":"Kremer Hovinga JA, Coppo P, Lammle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers. 2017;3:17020.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"4824_CR4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1152\/physrev.00037.2016","volume":"98","author":"RW Caldwell","year":"2018","unstructured":"Caldwell RW, Rodriguez PC, Toque HA, Narayanan SP, Caldwell RB. Arginase: a multifaceted enzyme important in health and disease. Physiol Rev. 2018;98(2):641\u201365.","journal-title":"Physiol Rev"},{"issue":"7","key":"4824_CR5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.2174\/156652408786241447","volume":"8","author":"CR Morris","year":"2008","unstructured":"Morris CR, Gladwin MT, Kato GJ. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med. 2008;8(7):620\u201332.","journal-title":"Curr Mol Med"},{"issue":"1","key":"4824_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jama.294.1.81","volume":"294","author":"CR Morris","year":"2005","unstructured":"Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005;294(1):81\u201390.","journal-title":"JAMA"},{"issue":"6","key":"4824_CR7","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/bjh.13452","volume":"169","author":"CR Morris","year":"2015","unstructured":"Morris CR, Kim HY, Klings ES, Wood J, Porter JB, Trachtenberg F, et al. Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. Br J Haematol. 2015;169(6):887\u201398.","journal-title":"Br J Haematol"},{"issue":"3","key":"4824_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1365-2141.2010.08096.x","volume":"149","author":"A Hill","year":"2010","unstructured":"Hill A, Rother RP, Wang X, Morris SM Jr, Quinn-Senger K, Kelly R, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2010;149(3):414\u201325.","journal-title":"Br J Haematol"},{"issue":"10","key":"4824_CR9","doi-asserted-by":"publisher","first-page":"2760S","DOI":"10.1093\/jn\/134.10.2760S","volume":"134","author":"DE Ash","year":"2004","unstructured":"Ash DE. Structure and function of arginases. J Nutr. 2004;134(10):2760S-S2764.","journal-title":"J Nutr"},{"issue":"5","key":"4824_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1189\/jlb.1109737","volume":"89","author":"R Rotondo","year":"2011","unstructured":"Rotondo R, Bertolotto M, Barisione G, Astigiano S, Mandruzzato S, Ottonello L, et al. Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J Leukoc Biol. 2011;89(5):721\u20137.","journal-title":"J Leukoc Biol"},{"key":"4824_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.metabol.2018.10.008","volume":"90","author":"A Kyselova","year":"2019","unstructured":"Kyselova A, Hinrichsmeyer H, Zukunft S, Mann AW, Dornauf I, Fleming I, Randriamboavonjy V. Association between arginase-containing platelet-derived microparticles and altered plasma arginine metabolism in polycystic ovary syndrome. Metabolism. 2019;90:16\u20139.","journal-title":"Metabolism"},{"issue":"3","key":"4824_CR12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/cvr\/cvt036","volume":"98","author":"J Pernow","year":"2013","unstructured":"Pernow J, Jung C. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? Cardiovasc Res. 2013;98(3):334\u201343.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"4824_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00726-008-0210-y","volume":"37","author":"G Wu","year":"2009","unstructured":"Wu G, Bazer FW, Davis TA, Kim SW, Li P, Marc Rhoads J, et al. Arginine metabolism and nutrition in growth, health and disease. Amino Acids. 2009;37(1):153\u201368.","journal-title":"Amino Acids"},{"issue":"5","key":"4824_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrcardio.2017.224","volume":"15","author":"C Farah","year":"2018","unstructured":"Farah C, Michel LYM, Balligand JL. Nitric oxide signalling in cardiovascular health and disease. Nat Rev Cardiol. 2018;15(5):292\u2013316.","journal-title":"Nat Rev Cardiol"},{"key":"4824_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155291","author":"GS Clemente","year":"2020","unstructured":"Clemente GS, van Waarde A, Antunes IF, Domling A, Elsinga PH. Arginase as a potential biomarker of disease progression: a molecular imaging perspective. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21155291.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4824_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00467-001-0792-z","volume":"17","author":"D Karpman","year":"2002","unstructured":"Karpman D, Bekassy ZD, Sj\u00f6gren AC, Dubois MS, Karmali MA, Mascarenhas M, et al. Antibodies to intimin and Escherichia coli secreted proteins A and B in patients with enterohemorrhagic Escherichia coli infections. Pediatr Nephrol. 2002;17(3):201\u201311.","journal-title":"Pediatr Nephrol"},{"issue":"20","key":"4824_CR17","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1182\/blood-2010-09-309161","volume":"117","author":"AL St\u00e5hl","year":"2011","unstructured":"St\u00e5hl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood. 2011;117(20):5503\u201313.","journal-title":"Blood"},{"issue":"2","key":"4824_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004619","volume":"11","author":"AL St\u00e5hl","year":"2015","unstructured":"St\u00e5hl AL, Arvidsson I, Johansson KE, Chromek M, Rebetz J, Loos S, et al. A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles. PLoS Pathog. 2015;11(2): e1004619.","journal-title":"PLoS Pathog"},{"issue":"6","key":"4824_CR19","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/BF00868714","volume":"9","author":"D Karpman","year":"1995","unstructured":"Karpman D, Andreasson A, Thysell H, Kaplan BS, Svanborg C. Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatr Nephrol. 1995;9(6):694\u20139.","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"4824_CR20","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/ndt\/gfq346","volume":"25","author":"R Schmitt","year":"2010","unstructured":"Schmitt R, Lindahl G, Karpman D. Antibody response to IgA-binding streptococcal M proteins in children with IgA nephropathy. Nephrol Dial Transplant. 2010;25(10):3434\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"4824_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/ki.1996.26","volume":"49","author":"D Karpman","year":"1996","unstructured":"Karpman D, Holmberg L, Jirg\u00e5rd L, Lethagen S. Increased platelet retention in familial recurrent thrombotic thrombocytopenic purpura. Kidney Int. 1996;49(1):190\u20139.","journal-title":"Kidney Int"},{"issue":"3","key":"4824_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00431-006-0354-2","volume":"166","author":"M Manea","year":"2007","unstructured":"Manea M, Kristoffersson AC, Tsai HM, Zhou W, Winqvist I, Oldaeus G, et al. ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. Eur J Pediatr. 2007;166(3):249\u201357.","journal-title":"Eur J Pediatr"},{"issue":"4","key":"4824_CR23","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.4049\/jimmunol.1502377","volume":"197","author":"I Arvidsson","year":"2016","unstructured":"Arvidsson I, Rebetz J, Loos S, Herthelius M, Kristoffersson AC, Englund E, et al. Early terminal complement blockade and C6 deficiency are protective in enterohemorrhagic Escherichia coli-infected mice. J Immunol. 2016;197(4):1276\u201386.","journal-title":"J Immunol"},{"issue":"6","key":"4824_CR24","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1128\/IAI.01024-10","volume":"79","author":"C Calderon Toledo","year":"2011","unstructured":"Calderon Toledo C, Arvidsson I, Karpman D. Cross-reactive protection against enterohemorrhagic Escherichia coli infection by enteropathogenic E. coli in a mouse model. Infect Immun. 2011;79(6):2224\u201333.","journal-title":"Infect Immun"},{"issue":"5","key":"4824_CR25","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.2353\/ajpath.2008.071218","volume":"173","author":"C Calderon Toledo","year":"2008","unstructured":"Calderon Toledo C, Rogers TJ, Svensson M, Tati R, Fischer H, Svanborg C, Karpman D. Shiga toxin-mediated disease in MyD88-deficient mice infected with Escherichia coli O157:H7. Am J Pathol. 2008;173(5):1428\u201339.","journal-title":"Am J Pathol"},{"issue":"11","key":"4824_CR26","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00467-010-1616-9","volume":"26","author":"ZD Bekassy","year":"2011","unstructured":"Bekassy ZD, Calderon Toledo C, Leoj G, Kristoffersson A, Leopold SR, Perez MT, Karpman D. Intestinal damage in enterohemorrhagic Escherichia coli infection. Pediatr Nephrol. 2011;26(11):2059\u201371.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"4824_CR27","doi-asserted-by":"publisher","first-page":"2122667","DOI":"10.1080\/19490976.2022.2122667","volume":"14","author":"I Arvidsson","year":"2022","unstructured":"Arvidsson I, Tontanahal A, Johansson K, Kristoffersson AC, Kellnerov\u00e1 S, Berger M, et al. Apyrase decreases phage induction and Shiga toxin release from E. coli O157:H7 and has a protective effect during infection. Gut Microbes. 2022;14(1):2122667.","journal-title":"Gut Microbes."},{"key":"4824_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113272","author":"R Greite","year":"2022","unstructured":"Greite R, Wang L, Gohlke L, Schott S, Kreimann K, Doricic J, et al. Cell-free hemoglobin in acute kidney injury after lung transplantation and experimental renal ischemia\/reperfusion. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232113272.","journal-title":"Int J Mol Sci."},{"issue":"7","key":"4824_CR29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676\u201382.","journal-title":"Nat Methods"},{"issue":"1","key":"4824_CR30","doi-asserted-by":"publisher","first-page":"14362","DOI":"10.1038\/s41598-019-50692-1","volume":"9","author":"KE Johansson","year":"2019","unstructured":"Johansson KE, St\u00e5hl AL, Arvidsson I, Loos S, Tontanahal A, Rebetz J, et al. Shiga toxin signals via ATP and its effect is blocked by purinergic receptor antagonism. Sci Rep. 2019;9(1):14362.","journal-title":"Sci Rep"},{"issue":"18","key":"4824_CR31","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14577","volume":"8","author":"O Richfield","year":"2020","unstructured":"Richfield O, Cortez R, Navar LG. Simulations of glomerular shear and hoop stresses in diabetes, hypertension, and reduced renal mass using a network model of a rat glomerulus. Physiol Rep. 2020;8(18): e14577.","journal-title":"Physiol Rep"},{"issue":"1","key":"4824_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12195-015-0424-5","volume":"9","author":"AK Wong","year":"2016","unstructured":"Wong AK, Llanos P, Boroda N, Rosenberg SR, Rabbany SY. A parallel-plate flow chamber for mechanical characterization of endothelial cells exposed to laminar shear stress. Cell Mol Bioeng. 2016;9(1):127\u201338.","journal-title":"Cell Mol Bioeng"},{"issue":"5","key":"4824_CR33","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1161\/01.RES.43.5.738","volume":"43","author":"HH Lipowsky","year":"1978","unstructured":"Lipowsky HH, Kovalcheck S, Zweifach BW. The distribution of blood rheological parameters in the microvasculature of cat mesentery. Circ Res. 1978;43(5):738\u201349.","journal-title":"Circ Res"},{"key":"4824_CR34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.freeradbiomed.2014.06.025","volume":"74","author":"B \u00c5kerstr\u00f6m","year":"2014","unstructured":"\u00c5kerstr\u00f6m B, Gram M. A1M, an extravascular tissue cleaning and housekeeping protein. Free Radic Biol Med. 2014;74:274\u201382.","journal-title":"Free Radic Biol Med"},{"key":"4824_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/3763250","volume":"2016","author":"N Kiss","year":"2016","unstructured":"Kiss N, Hamar P. Histopathological evaluation of contrast-induced acute kidney injury rodent models. Biomed Res Int. 2016;2016:1\u201315.","journal-title":"Biomed Res Int."},{"issue":"3","key":"4824_CR36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/infdis\/175.3.611","volume":"175","author":"D Karpman","year":"1997","unstructured":"Karpman D, Connell H, Svensson M, Scheutz F, Alm P, Svanborg C. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J Infect Dis. 1997;175(3):611\u201320.","journal-title":"J Infect Dis"},{"key":"4824_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-physiol-020518-114605","volume":"81","author":"WR Zhang","year":"2019","unstructured":"Zhang WR, Parikh CR. Biomarkers of acute and chronic kidney disease. Annu Rev Physiol. 2019;81:309\u201333.","journal-title":"Annu Rev Physiol"},{"issue":"5","key":"4824_CR38","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.4049\/jimmunol.1301221","volume":"191","author":"R Tati","year":"2013","unstructured":"Tati R, Kristoffersson AC, St\u00e5hl AL, Rebetz J, Wang L, Licht C, et al. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol. 2013;191(5):2184\u201393.","journal-title":"J Immunol"},{"issue":"11","key":"4824_CR39","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00467-010-1522-1","volume":"25","author":"C Zoja","year":"2010","unstructured":"Zoja C, Buelli S, Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatric Nephrol. 2010;25(11):2231\u201340.","journal-title":"Pediatric Nephrol"},{"issue":"9","key":"4824_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006990","volume":"4","author":"AL St\u00e5hl","year":"2009","unstructured":"St\u00e5hl AL, Sartz L, Nelsson A, Bekassy ZD, Karpman D. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS ONE. 2009;4(9): e6990.","journal-title":"PLoS ONE"},{"issue":"02","key":"4824_CR41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1055\/s-2006-939769","volume":"32","author":"D Karpman","year":"2006","unstructured":"Karpman D, Manea M, Vaziri-Sani F, St\u00e5hl AL, Kristoffersson AC. Platelet activation in hemolytic uremic syndrome. Semin Thromb Hemost. 2006;32(02):128\u201345.","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"4824_CR42","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.4049\/jimmunol.1402470","volume":"194","author":"I Arvidsson","year":"2015","unstructured":"Arvidsson I, St\u00e5hl AL, Hedstr\u00f6m MM, Kristoffersson AC, Rylander C, Westman JS, et al. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol. 2015;194(5):2309\u201318.","journal-title":"J Immunol"},{"issue":"3","key":"4824_CR43","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/med.21419","volume":"37","author":"M Pudlo","year":"2017","unstructured":"Pudlo M, Demougeot C, Girard-Thernier C. Arginase inhibitors: a rational approach over one century. Med Res Rev. 2017;37(3):475\u2013513.","journal-title":"Med Res Rev"},{"key":"4824_CR44","unstructured":"Clinicaltrials.gov, National Library of Medicine, Bethesda, MD. Identifier: NCT02903914. Arginase inhibitor INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced\/metastatic solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT02903914."},{"key":"4824_CR45","doi-asserted-by":"publisher","first-page":"1023023","DOI":"10.3389\/fimmu.2022.1023023","volume":"13","author":"CL Lorentzen","year":"2022","unstructured":"Lorentzen CL, Martinenaite E, Kjeldsen JW, Holmstroem RB, Mork SK, Pedersen AW, et al. Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors\u2014a phase I trial. Front Immunol. 2022;13:1023023.","journal-title":"Front Immunol"},{"issue":"1","key":"4824_CR46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13075-018-1616-x","volume":"20","author":"UM Chandrasekharan","year":"2018","unstructured":"Chandrasekharan UM, Wang Z, Wu Y, Wilson Tang WH, Hazen SL, Wang S, Elaine HM. Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis. Arthritis Res Ther. 2018;20(1):123.","journal-title":"Arthritis Res Ther"},{"key":"4824_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/nu15092162","author":"LZ Reyes","year":"2023","unstructured":"Reyes LZ, Winterberg PD, George RP, Kelleman M, Harris F, Jo H, et al. Arginine dysregulation and myocardial dysfunction in a mouse model and children with chronic kidney disease. Nutrients. 2023. https:\/\/doi.org\/10.3390\/nu15092162.","journal-title":"Nutrients."},{"issue":"1","key":"4824_CR48","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/CH-2012-1617","volume":"54","author":"F Quitter","year":"2013","unstructured":"Quitter F, Figulla HR, Ferrari M, Pernow J, Jung C. Increased arginase levels in heart failure represent a therapeutic target to rescue microvascular perfusion. Clin Hemorheol Microcirc. 2013;54(1):75\u201385.","journal-title":"Clin Hemorheol Microcirc"},{"key":"4824_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9061143","author":"A Tontanahal","year":"2021","unstructured":"Tontanahal A, Arvidsson I, Karpman D. Annexin induces cellular uptake of extracellular vesicles and delays disease in Escherichia coli O157:H7 infection. Microorganisms. 2021. https:\/\/doi.org\/10.3390\/microorganisms9061143.","journal-title":"Microorganisms"},{"issue":"2","key":"4824_CR50","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1128\/IAI.66.2.636-644.1998","volume":"66","author":"D Karpman","year":"1998","unstructured":"Karpman D, H\u00e5kansson A, Perez MT, Isaksson C, Carlemalm E, Caprioli A, Svanborg C. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: in vivo and in vitro studies. Infect Immun. 1998;66(2):636\u201344.","journal-title":"Infect Immun"},{"key":"4824_CR51","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.EHEC-0009-2013","author":"D Karpman","year":"2014","unstructured":"Karpman D, Stahl AL. Enterohemorrhagic Escherichia coli pathogenesis and the host response. Microbiol Spectr. 2014. https:\/\/doi.org\/10.1128\/microbiolspec.EHEC-0009-2013.","journal-title":"Microbiol Spectr."},{"key":"4824_CR52","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/203512","volume":"2014","author":"NK Kanzelmeyer","year":"2014","unstructured":"Kanzelmeyer NK, Pape L, Chobanyan-Jurgens K, Tsikas D, Hartmann H, Fuchs AJ, et al. L-arginine\/NO pathway is altered in children with haemolytic-uraemic syndrome (HUS). Oxid Med Cell Longev. 2014;2014: 203512.","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"4824_CR53","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1161\/01.CIR.93.2.208","volume":"93","author":"AJ Marcus","year":"1996","unstructured":"Marcus AJ, Broekman MJ. Cell-free hemoglobin as an oxygen carrier removes nitric oxide, resulting in defective thromboregulation. Circulation. 1996;93(2):208\u20139.","journal-title":"Circulation"},{"issue":"5","key":"4824_CR54","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/08860220500200841","volume":"27","author":"RL Siegler","year":"2005","unstructured":"Siegler RL, Pysher TJ, Tesh VL, Noris M, Cassis P, Taylor FB Jr. Reduced nitric oxide bioavailability in a baboon model of Shiga toxin mediated hemolytic uremic syndrome (HUS). Ren Fail. 2005;27(5):635\u201341.","journal-title":"Ren Fail"},{"issue":"4","key":"4824_CR55","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1111\/j.1523-1755.2002.kid554.x","volume":"62","author":"GI Dran","year":"2002","unstructured":"Dran GI, Fernandez GC, Rubel CJ, Bermejo E, Gomez S, Meiss R, et al. Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome. Kidney Int. 2002;62(4):1338\u201348.","journal-title":"Kidney Int"},{"issue":"3","key":"4824_CR56","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0306-9877(97)90213-9","volume":"49","author":"ZW Jaradat","year":"1997","unstructured":"Jaradat ZW, Marquardt RR. L-arginine as a therapeutic approach for the verotoxigenic Escherichia coli-induced hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Med Hypotheses. 1997;49(3):277\u201380.","journal-title":"Med Hypotheses"},{"issue":"4","key":"4824_CR57","doi-asserted-by":"publisher","first-page":"F922","DOI":"10.1152\/ajprenal.00375.2018","volume":"317","author":"CM Shaver","year":"2019","unstructured":"Shaver CM, Paul MG, Putz ND, Landstreet SR, Kuck JL, Scarfe L, et al. Cell-free hemoglobin augments acute kidney injury during experimental sepsis. Am J Physiol Renal Physiol. 2019;317(4):F922\u20139.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"4824_CR58","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1172\/JCI62972","volume":"122","author":"MT Gladwin","year":"2012","unstructured":"Gladwin MT, Kanias T, Kim-Shapiro DB. Hemolysis and cell-free hemoglobin drive an intrinsic mechanism for human disease. J Clin Invest. 2012;122(4):1205\u20138.","journal-title":"J Clin Invest"},{"issue":"17","key":"4824_CR59","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1182\/blood.2022015596","volume":"140","author":"F Vallelian","year":"2022","unstructured":"Vallelian F, Buehler PW, Schaer DJ. Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics. Blood. 2022;140(17):1837\u201344.","journal-title":"Blood"},{"key":"4824_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.645650","volume":"12","author":"J Bergwik","year":"2021","unstructured":"Bergwik J, Kristiansson A, Allhorn M, Gram M, \u00c5kerstr\u00f6m B. Structure, functions, and physiological roles of the lipocalin alpha(1)-microglobulin (A1M). Front Physiol. 2021;12: 645650.","journal-title":"Front Physiol"},{"key":"4824_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2019.106386","volume":"146","author":"KM Rund","year":"2020","unstructured":"Rund KM, Peng S, Greite R, Claassen C, Nolte F, Oger C, et al. Dietary omega-3 PUFA improved tubular function after ischemia induced acute kidney injury in mice but did not attenuate impairment of renal function. Prostaglandins Other Lipid Mediat. 2020;146: 106386.","journal-title":"Prostaglandins Other Lipid Mediat"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04824-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04824-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04824-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T12:04:06Z","timestamp":1704369846000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04824-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4824"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04824-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"29 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the Declaration of Helsinki with the approval of the Regional Ethics review board of Lund University, the Swedish Ethical Review Authority, and the committee for protection of human subjects at the Children\u2019s Hospital of Philadelphia. Written informed consent was obtained from the patients, or their parents, and the controls. All patients from the Children\u2019s Hospital of Philadelphia gave initial IRB-approved informed consent and their samples were later de-identified. The study and approvals included the use of anonymized blood samples (serum samples from the Children\u2019s Hospital of Philadelphia and certain pediatric controls). All animal experiments, including <i>E. coli<\/i> O157:H7 infection and Shiga toxin injection, were approved by the regional Animal Ethics Committee (approvals M76-15 and 17452-20) and performed in accordance with regulations of the Swedish Board of Agriculture and the European Directive on the protection of animals used for scientific purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}